Oral lichen planus is a chronic inflammatory condition affecting the lining of the mouth, causing symptoms ranging from painless white patches to painful sores and bright red gums. While there is no cure, various treatment approaches — both standard therapies approved by medical societies and innovative drugs tested in clinical trials — aim to relieve discomfort, heal lesions, and improve patients’ quality of life.

Managing a Persistent Oral Condition: What Treatment Can Achieve

Oral lichen planus is a lifelong condition that follows a pattern of flare-ups and periods of calm. Because the exact cause remains unclear, treatment does not eliminate the disease but instead focuses on controlling symptoms and preventing complications. The main goals are to reduce pain, heal open sores or erosions in the mouth, and minimize the risk of more serious problems such as secondary infections or, in rare cases, oral cancer. Treatment also aims to help patients maintain good oral hygiene and enjoy eating without discomfort.^[1][2]

Not everyone with oral lichen planus needs treatment. The mild form, known as reticular oral lichen planus, usually appears as white, lacy streaks inside the cheeks and often causes no pain or irritation. Many people with this type can live comfortably without medication. However, the more severe form, called erosive oral lichen planus, produces bright red, inflamed gums, open ulcers, and intense burning sensations, especially when eating hot, acidic, or spicy foods. This form requires active management to ease suffering and promote healing.^[2][9]

Treatment plans depend on the type and severity of lesions, the patient’s overall health, and how much the condition interferes with daily life. Healthcare providers choose therapies based on clinical guidelines from medical societies and tailor them to each patient’s needs. Because oral lichen planus is chronic, patients need regular monitoring by a dentist or oral medicine specialist to watch for changes, adjust treatments, and catch any signs of complications early.^[4][9]

Standard Treatments: What Doctors Typically Prescribe

The cornerstone of standard treatment for oral lichen planus is topical corticosteroids, which are medicines applied directly to the affected areas inside the mouth. These drugs work by reducing inflammation and calming the overactive immune response that damages the mouth’s lining. High-potency topical corticosteroids such as clobetasol are considered first-line therapy for all forms of oral lichen planus, including painful erosive lesions. Patients apply these creams, gels, or ointments to the affected areas several times a day, often for weeks or months.^[5][9][13]

Topical corticosteroids are generally safe when used as directed, but prolonged use can lead to side effects. One common problem is oral candidiasis, a fungal infection that appears as white, creamy patches in the mouth. Although this infection is usually not serious, doctors may prescribe antifungal medications such as nystatin or amphotericin to treat it. Patients using topical steroids should follow their healthcare provider’s instructions carefully and report any new symptoms.^[16][5]

When topical steroids alone do not provide enough relief, doctors may consider other options. Intralesional corticosteroid injections involve injecting a steroid such as triamcinolone acetonide directly into thick or stubborn lesions. This approach delivers medication precisely where it is needed and can be particularly effective for localized, difficult-to-treat patches.^[13][16]

For patients with widespread, severe oral lichen planus that does not respond to topical treatment, systemic corticosteroids taken by mouth may be necessary. A typical course involves taking prednisone tablets at a starting dose of 30 to 60 milligrams per day, then gradually reducing the dose over three to six weeks. Systemic steroids work throughout the body and can bring rapid improvement, but they carry more risks than topical forms. Long-term use can lead to weight gain, high blood sugar, weakened bones, and increased susceptibility to infections. Therefore, doctors reserve systemic steroids for severe cases and use them for the shortest time possible.^[13][16]

Another class of medications used as second-line therapy includes topical calcineurin inhibitors such as tacrolimus and pimecrolimus. These drugs also suppress the immune system but work through a different mechanism than corticosteroids. Tacrolimus ointment applied to oral lesions has shown good results in patients who do not respond to or cannot tolerate topical steroids. Calcineurin inhibitors are especially useful for treating erosive oral lichen planus and lesions affecting the gums and genital areas.^[13][16]

For patients with very resistant oral lichen planus, doctors may try other immunosuppressive drugs taken by mouth or applied topically. These include medications such as cyclosporine, azathioprine, mycophenolate mofetil, hydroxychloroquine, and dapsone. These drugs are more complex to use and require close monitoring because they can affect blood cell counts, liver function, and other body systems. Only healthcare professionals experienced with these medications should prescribe them.^[16][5]

Systemic retinoids, a type of vitamin A derivative, have also been used to treat severe oral lichen planus. One example is acitretin, an oral medication that can help reduce lesions, but it is expensive and can cause side effects such as dry skin, hair loss, and elevated blood fats. Retinoids are generally considered only when other treatments have failed.^[16]

Physical treatments such as photodynamic therapy, phototherapy, cryotherapy, and laser therapy are occasionally used for oral lichen planus. These methods involve using light, cold, or laser energy to target and reduce inflamed tissue. However, evidence supporting their effectiveness is limited, and they are not widely used as standard treatments.^[5]

Some patients find relief with topical numbing agents such as lidocaine applied directly to very painful areas before eating or brushing teeth. These provide temporary relief and can make daily activities more comfortable, though they do not treat the underlying inflammation.^[9]

Duration of treatment varies widely. Some patients need medication continuously to keep symptoms under control, while others can stop treatment during periods of remission. Doctors adjust treatment plans based on how well lesions heal and whether symptoms return. Regular follow-up appointments are essential to monitor progress and prevent complications.^[9][4]

Innovative Therapies Being Tested in Clinical Trials

Researchers are exploring new ways to treat oral lichen planus, particularly for patients whose condition does not respond to standard therapies. Clinical trials are testing innovative drugs and treatment approaches that target specific parts of the immune system believed to drive the disease. These studies are conducted in multiple phases: Phase I tests safety and appropriate dosing in small groups of volunteers; Phase II evaluates whether the treatment works and continues to monitor safety in larger groups; and Phase III compares the new treatment to standard therapies in even larger populations to confirm effectiveness and safety.^[11]

One promising area of research involves drugs that block specific interleukins, which are immune signaling molecules that contribute to inflammation. Studies have found elevated levels of certain interleukins, particularly interleukin-17 (IL-17) and interleukin-23 (IL-23), in patients with oral lichen planus. Blocking these molecules with targeted antibodies could reduce inflammation and lesion severity.^[11]

Anti-IL-17 agents are biologic drugs that specifically block the action of IL-17, a protein that promotes inflammation and tissue damage. Several clinical reports and case studies have shown that patients with severe, treatment-resistant oral lichen planus experienced significant improvement when treated with anti-IL-17 drugs. These medications, which are already approved for other inflammatory conditions such as psoriasis, work by stopping IL-17 from activating immune cells that attack the mouth’s lining. Patients receiving these therapies reported reduced pain, healing of erosions, and better quality of life.^[11]

Similarly, anti-IL-12/23 agents and anti-IL-23 agents are being studied for oral lichen planus. These drugs block interleukin-12 and interleukin-23, proteins involved in activating the immune cells that damage oral tissue. Early reports suggest that these biologics can effectively control symptoms in patients who have not responded to corticosteroids or other standard treatments. Because these drugs are highly specific, they may cause fewer side effects than broad immunosuppressive medications.^[11]

Biologic therapies are typically given as injections under the skin or infusions into a vein. Treatment schedules vary depending on the specific drug, but many biologics are administered every few weeks or months. While these therapies are expensive and require careful monitoring, they offer hope for patients with severe, refractory oral lichen planus who have exhausted other options.^[11]

Another experimental treatment involves platelet-rich plasma (PRP) and platelet-rich fibrin (PRF). These therapies use components from the patient’s own blood to promote healing. Blood is drawn, processed to concentrate platelets and growth factors, and then injected into the affected areas of the mouth. Some studies have compared PRP and PRF to intralesional corticosteroids and found that all three approaches produced similar improvements in pain and lesion healing. While more research is needed, these treatments could become alternatives for patients seeking non-drug options.^[16]

Researchers are also investigating topical curcumin, a natural compound derived from turmeric, as a potential treatment for oral lichen planus. Curcumin has anti-inflammatory properties and may help reduce pain and promote healing when applied directly to oral lesions. Some small studies have shown promising results, but larger, well-designed clinical trials are needed to confirm its effectiveness and safety.^[16]

Thalidomide, a drug known to suppress tumor necrosis factor (TNF), a key inflammatory molecule, has been tested in oral lichen planus patients. Some reports indicate that thalidomide can be effective in severe cases. However, thalidomide carries serious risks, including birth defects and nerve damage, and is tightly regulated. Only specially trained doctors can prescribe it, and patients must follow strict safety protocols.^[5]

Understanding the mechanisms of action of these experimental therapies is important. Many of the drugs being tested work by targeting specific immune pathways. For example, anti-IL-17 and anti-IL-23 drugs block the signals that activate T-cells, a type of white blood cell that mistakenly attacks the mouth’s lining in oral lichen planus. By interrupting these signals, the drugs reduce inflammation and allow damaged tissue to heal. This precision targeting contrasts with older immunosuppressive drugs that broadly suppress the entire immune system and can lead to more side effects.^[5][11]

Preliminary results from clinical trials have been encouraging. Patients treated with biologics targeting interleukins often experience significant reductions in pain, healing of erosions, and improvement in their ability to eat and speak comfortably. The safety profiles of these drugs have generally been favorable, though side effects such as increased risk of infections, injection site reactions, and allergic responses can occur. Long-term safety data are still being collected.^[11]

Research into oral lichen planus continues to evolve. Scientists are studying the role of microRNA, small molecules that regulate gene expression, in the disease. One study identified elevated levels of microRNA-4484 (miR-4484) in the saliva of patients with oral lichen planus. Understanding how these molecules contribute to the disease could lead to new diagnostic tests and targeted therapies.^[5]

As more is learned about the underlying causes of oral lichen planus, new treatments targeting specific molecules, pathways, or immune cells will likely emerge. The development of biologics and other innovative therapies offers hope that one day, highly effective and safe treatments will be available for all patients with this challenging condition.^[11]

Most common treatment methods

• Topical corticosteroids
  • High-potency topical corticosteroids such as clobetasol applied directly to oral lesions
  • First-line therapy for reticular and erosive oral lichen planus
  • Applied several times daily to reduce inflammation and promote healing
• Intralesional corticosteroid injections
  • Injection of triamcinolone acetonide directly into stubborn lesions
  • Effective for localized, difficult-to-treat patches
• Systemic corticosteroids
  • Oral prednisone at starting doses of 30 to 60 mg per day, tapered over three to six weeks
  • Reserved for severe, widespread oral lichen planus
• Topical calcineurin inhibitors
  • Tacrolimus and pimecrolimus applied to lesions as second-line therapy
  • Useful for patients who do not respond to or cannot tolerate topical steroids
• Systemic immunosuppressive drugs
  • Cyclosporine, azathioprine, mycophenolate mofetil, hydroxychloroquine, and dapsone for refractory cases
  • Require close monitoring due to potential side effects
• Systemic retinoids
  • Acitretin, an oral vitamin A derivative, for severe cases
  • Can cause side effects such as dry skin and elevated blood fats
• Physical interventions
  • Photodynamic therapy, phototherapy, cryotherapy, and laser therapy
  • Occasionally used but with limited evidence of effectiveness
• Topical numbing agents
  • Lidocaine applied to very painful areas for temporary relief
• Biologic therapies (clinical trials)
  • Anti-IL-17 agents targeting interleukin-17 to reduce inflammation
  • Anti-IL-12/23 and anti-IL-23 agents blocking immune signaling molecules
  • Promising results in refractory oral lichen planus
• Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF)
  • Experimental therapies using the patient’s own blood components to promote healing
  • Comparable effectiveness to intralesional corticosteroids in some studies
• Topical curcumin
  • Natural anti-inflammatory compound applied to oral lesions
  • Some evidence of pain relief and healing promotion
• Thalidomide
  • Experimental treatment for severe cases
  • Suppresses tumor necrosis factor (TNF) but carries serious risks and is tightly regulated